Novacea acquires rights to oral vinorelbine
Pierre Fabre has licensed the US and Canadian rights for oral vinorelbine to Novacea, while Pierre Fabre will continue to develop and commercialize oral vinorelbine in Europe and
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.